Vigil Neuroscience, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Sanofi has finalized its acquisition of Vigil Neuroscience, Inc., converting Vigil shares into cash and contingent value rights tied to the clinical candidate VG-3927.
Vigil Neuroscience, Inc. has voluntarily supplemented its definitive proxy statement for the Sanofi merger to address shareholder demands alleging material omissions, while denying the necessity of such disclosures.
A significant regulatory condition for the acquisition of Vigil Neuroscience by Sanofi has been satisfied, moving the merger closer to completion.
Vigil Neuroscience, Inc. announced that its stockholders approved the election of two Class I directors and ratified PricewaterhouseCoopers LLP as its independent auditor for 2025 at the Annual Meeting held on May 22, 2025.
Sanofi will acquire Vigil Neuroscience for $8.00 per share in cash, plus a contingent value right of $2.00 per share, potentially totaling $600 million, to enhance its neurology and immunology focus.
8-K: Vigil Neuroscience Reports Positive Phase 1 Data and Anticipates Key Clinical Milestones in 2025
Vigil Neuroscience announces its Q1 2025 financial results and provides updates on its clinical programs, including plans to initiate a Phase 2 trial for VG-3927 in Alzheimer's disease and report final analysis from the IGNITE Phase 2 trial for iluzanebart in ALSP.
Vigil Neuroscience reports positive Phase 1 data for VG-3927, plans Phase 2 trial, and anticipates final analysis from IGNITE Phase 2 trial in Q2 2025.
Vigil Neuroscience reports positive Phase 1 clinical trial data for VG-3927, showing a favorable safety profile and significant target engagement, paving the way for a Phase 2 trial.
Vigil Neuroscience announced its third quarter 2024 financial results and provided updates on its clinical programs, including plans for final analysis of the IGNITE trial and progress in the Phase 1 trial of VG-3927.
The FDA has removed the partial clinical hold on Vigil Neuroscience's Phase 1 trial of VG-3927, allowing for further exploration of the drug's potential in treating Alzheimer's disease.
Vigil Neuroscience reported second quarter 2024 financial results, highlighted a $40 million strategic investment from Sanofi, and provided updates on their clinical programs for iluzanebart and VG-3927.
8-K: Vigil Neuroscience Announces Positive Interim Phase 1 Data for Alzheimer's Drug Candidate VG-3927
Vigil Neuroscience reports encouraging interim data from its Phase 1 trial of VG-3927, showing a favorable safety profile and target engagement for its Alzheimer's disease treatment.
Vigil Neuroscience is modifying its clinical development strategy for iluzanebart, focusing on a 12-month final analysis to potentially pursue an accelerated approval pathway.
Vigil Neuroscience has received a $40 million strategic investment from Sanofi, which includes a right of first negotiation for their small molecule TREM2 agonist program.
Vigil Neuroscience's stockholders approved amendments to the company's charter and bylaws, including officer exculpation and remote meeting provisions, and elected three Class III directors at the 2024 Annual Meeting.
Vigil Neuroscience reported its first quarter 2024 financial results and provided updates on its clinical programs, including the completion of enrollment for a Phase 2 trial and the anticipation of key data readouts in 2024.
Vigil Neuroscience announced positive interim data from its Phase 2 IGNITE trial for iluzanebart, completed enrollment for the trial, and provided a business update alongside its 2023 financial results.
Vigil Neuroscience provided an update on its clinical programs at the J.P. Morgan Healthcare Conference, focusing on its lead candidates for ALSP and Alzheimer's disease.